The Australia and Japan Cell Therapy Market Share Size Analysis 2022-2029

The Australia and Japan Cell Therapy Market Share Size Analysis 2022-2029

The Australia and Japan hydrogen electrolyzer market is expected to grow at a CAGR of 21.2% during the forecast period 2022- 2029.

2021-05-25

Growing Demand For Blood Plasma in Biopharmaceutical Companies

The rising demand for blood plasma in biopharmaceutical companies is also one of the major factors leading to growth of the apheresis market.

The demand for blood proteins is expanding due to new indications, better access and an aging population. Plasma fractionation companies adapt to this strongly growing market demand by maximizing their facility throughput and by making their facilities more flexible. In addition, yield optimization and process characterization is increasingly important. Product diversification such as recombinant processes open new possibilities with regard to new indications and help to satisfy the increasing market demand. Plasma-derived medicinal products (PDMPs) are prepared industrially from human plasma by pharmaceutical companies1 and include products such as albumin, coagulation factors and immunoglobulins, which are life-saving therapeutics for several chronic and acute life-threatening diseases HSA is one of the world’s most used intravenous proteins and is an alternative to donor blood. Clinical applications include stabilising blood volume during surgery. Human serum albumin (HSA) demand in Japan is estimated at 5.9 million vials a year. Of this, 3.9 million vials are sourced from Japan and the additional two million are made from imported blood plasma.

Rising Advancements In Technology

Advances in technology in the apheresis devices have led to the development of customized devices as per patient requirement.  The major manufacturers  are investing in R&D to design and manufacture innovative apheresis systems that are automated, patient friendly, and provide accurate results.  Automated cell processors and blood collection devices have become standard systems for blood collection. These devices separate the required blood components rather than the whole blood, helping to optimize blood usage. Vendors are offering a wide range of cell separators that use microfiltration and centrifugation technologies to separate blood components.

Next-generation blood cell separators are also available in the market. For instance, Terumo BCT's Spectra Optia apheresis system is a popular next-generation cell separator. The equipment consists of an automated interface management system and ready-to-use tubing sets. These two features help to reduce the processing and separation time of blood components and make the donation process more comfortable for blood donors.

Advances in cell separator technology also allow control over the anticoagulant volume, provide the flexibility of changing blood volume, and collect blood from multiple donors in one sitting.

In March 2019, Kaneka Pharma America received the FDA approval for the modification of the indications for the use (IFU) of Kaneka’s LIPOSORBER® LA-15 system. This approval will allow more US patients to use the apheresis treatment to lower low-density lipoprotein cholesterol (LDL-C) levels.

Market Opportunities

The growing demand for apheresis machines owing to its durability and extensive use in the transfusion treatment is expected to lead to the market growth. In addition, availability of higher class of machines for efficient separation of various blood and plasma components will further create vast growth opportunities for the Japan apheresis market. A trend observed in the Japan apheresis market is the increasing focus over apheresis devices, which is expected to further bolster growth of the target market to a significant extent during the forecast period. Market players involved in apheresis are developing automated apheresis products, which is likely to promote the market growth in the coming years. For instance, the Spectra Optia (Optia, Terumo BCT) was introduced as an automated apheresis instrument, but comparisons with other instruments have been few. This is the first randomized multicenter and crossover comparison of the Optia with the automated program of the established apheresis instrument, the Spectra (Spectra-Auto, Terumo BCT). Also, upsurge in demand for blood components across the region and increase in government initiatives towards blood donation is expected to create huge oppurtunities for the market. These developments will create growth opportunities for the market during the forecast period.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

Found it interesting?

Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866

We have 5000+ marketing reports and serve across 130+ countries

Tags:

#Japan Apheresis Market, #Japan Apheresis Market size, #Japan Apheresis Market share, #Japan Apheresis Market trends, #Japan Apheresis Market value, #Japan Apheresis Market growth, #Japan Apheresis Market demand, #Japan Apheresis Market industry forecast, #Japan Apheresis Market outlook, #Japan Apheresis Market analysis, #Japan Apheresis Market applications, #Japan Apheresis Market companies, #datamintelligence